176 related articles for article (PubMed ID: 36111395)
1. Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel.
Porter TJ; Lazarevic A; Ziggas JE; Fuchs E; Kim K; Byrnes H; Luznik L; Bolaños-Meade J; Ali SA; Shah NN; Wagner-Johnston N; Jain T
Br J Haematol; 2022 Dec; 199(5):720-727. PubMed ID: 36111395
[TBL] [Abstract][Full Text] [Related]
2. Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel.
Cutini I; Puccini B; Fabbri A; Santi R; Gozzini A; Nozzoli C; Boncompagni R; Innocenti C; Saccardi R
Transpl Immunol; 2022 Dec; 75():101719. PubMed ID: 36116729
[TBL] [Abstract][Full Text] [Related]
3. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Hines MR; Knight TE; McNerney KO; Leick MB; Jain T; Ahmed S; Frigault MJ; Hill JA; Jain MD; Johnson WT; Lin Y; Mahadeo KM; Maron GM; Marsh RA; Neelapu SS; Nikiforow S; Ombrello AK; Shah NN; Talleur AC; Turicek D; Vatsayan A; Wong SW; Maus MV; Komanduri KV; Berliner N; Henter JI; Perales MA; Frey NV; Teachey DT; Frank MJ; Shah NN
Transplant Cell Ther; 2023 Jul; 29(7):438.e1-438.e16. PubMed ID: 36906275
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.
Hines MR; Keenan C; Maron Alfaro G; Cheng C; Zhou Y; Sharma A; Hurley C; Nichols KE; Gottschalk S; Triplett BM; Talleur AC
Br J Haematol; 2021 Aug; 194(4):701-707. PubMed ID: 34263927
[TBL] [Abstract][Full Text] [Related]
5. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).
Sandler RD; Tattersall RS; Schoemans H; Greco R; Badoglio M; Labopin M; Alexander T; Kirgizov K; Rovira M; Saif M; Saccardi R; Delgado J; Peric Z; Koenecke C; Penack O; Basak G; Snowden JA
Front Immunol; 2020; 11():524. PubMed ID: 32296434
[No Abstract] [Full Text] [Related]
7. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
8. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
[TBL] [Abstract][Full Text] [Related]
9. Diagnosing haemophagocytic syndrome.
Sen ES; Steward CG; Ramanan AV
Arch Dis Child; 2017 Mar; 102(3):279-284. PubMed ID: 27831908
[TBL] [Abstract][Full Text] [Related]
10. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.
Hashmi H; Bachmeier C; Chavez JC; Song J; Hussaini M; Krivenko G; Nishihori T; Kotani H; Davila ML; Locke FL; Jain MD
Br J Haematol; 2019 Oct; 187(2):e35-e38. PubMed ID: 31410842
[No Abstract] [Full Text] [Related]
11. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
[TBL] [Abstract][Full Text] [Related]
13. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.
Ishii K; Pouzolles M; Chien CD; Erwin-Cohen RA; Kohler ME; Qin H; Lei H; Kuhn S; Ombrello AK; Dulau-Florea A; Eckhaus MA; Shalabi H; Yates B; Lichtenstein DA; Zimmermann VS; Kondo T; Shern JF; Young HA; Taylor N; Shah NN; Fry TJ
J Clin Invest; 2020 Oct; 130(10):5425-5443. PubMed ID: 32925169
[TBL] [Abstract][Full Text] [Related]
14. Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
Kim DW; Bukhari A; Lutfi F; Zafforoni F; Merechi F; Mustafa Ali MK; Gottlieb D; Lee ST; Kocoglu MH; Hardy NM; Yared J; Rapoport AP; Dahiya S; Law JY
Leuk Lymphoma; 2022 Jun; 63(6):1339-1347. PubMed ID: 35045791
[TBL] [Abstract][Full Text] [Related]
15. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
Deshpande A; Wang Y; Munoz J; Jain P
Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
[TBL] [Abstract][Full Text] [Related]
16. Does your unwell patient have haemophagocytic lymphohistiocytosis?
Holloway A; Ahmed S; Manson JJ
Br J Hosp Med (Lond); 2024 Mar; 85(3):1-12. PubMed ID: 38557089
[TBL] [Abstract][Full Text] [Related]
17. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
Locke FL; Go WY; Neelapu SS
JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
[TBL] [Abstract][Full Text] [Related]
18. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
19. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
Lichtenstein DA; Schischlik F; Shao L; Steinberg SM; Yates B; Wang HW; Wang Y; Inglefield J; Dulau-Florea A; Ceppi F; Hermida LC; Stringaris K; Dunham K; Homan P; Jailwala P; Mirazee J; Robinson W; Chisholm KM; Yuan C; Stetler-Stevenson M; Ombrello AK; Jin J; Fry TJ; Taylor N; Highfill SL; Jin P; Gardner RA; Shalabi H; Ruppin E; Stroncek DF; Shah NN
Blood; 2021 Dec; 138(24):2469-2484. PubMed ID: 34525183
[TBL] [Abstract][Full Text] [Related]
20. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
Major A; Collins J; Craney C; Heitman AK; Bauer E; Zerante E; Stock W; Bishop MR; Jasielec J
Leuk Lymphoma; 2021 Jul; 62(7):1765-1769. PubMed ID: 33559517
[No Abstract] [Full Text] [Related]
[Next] [New Search]